Glenmark Specialty S.A., a wholly-owned subsidiary of Glenmark Pharmaceuticals, announced that China’s National Medical Products Administration (NMPA) has approved RYALTRIS Compound Nasal Spray (GSP 301 NS) for the treatment of allergic rhinitis (AR). The therapy is now authorized for moderate to severe seasonal AR in adults and children aged 6 years and older, and for moderate to severe perennial AR in adults and adolescents aged 12 years and above.
The approval—granted with zero supplementation requests—represents a significant milestone for Glenmark’s respiratory portfolio and highlights the company’s progress in developing innovative, differentiated therapies for patients managing chronic respiratory conditions.
Read More